- Home
- JGH vs ADCT Comparison
JGH vs ADCT Comparison
Compare JGH & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- ADCT
- Stock Information
- Founded
- JGH 2014
- ADCT 2011
- Country
- JGH United States
- ADCT Switzerland
- Employees
- JGH N/A
- ADCT N/A
- Industry
- JGH Investment Managers
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- ADCT Health Care
- Exchange
- JGH Nasdaq
- ADCT Nasdaq
- Market Cap
- JGH 285.5M
- ADCT 241.0M
- IPO Year
- JGH N/A
- ADCT 2020
- Fundamental
- Price
- JGH $12.67
- ADCT $3.76
- Analyst Decision
- JGH
- ADCT Strong Buy
- Analyst Count
- JGH 0
- ADCT 5
- Target Price
- JGH N/A
- ADCT $7.75
- AVG Volume (30 Days)
- JGH 73.9K
- ADCT 807.5K
- Earning Date
- JGH 01-01-0001
- ADCT 05-14-2025
- Dividend Yield
- JGH 9.85%
- ADCT N/A
- EPS Growth
- JGH N/A
- ADCT N/A
- EPS
- JGH N/A
- ADCT N/A
- Revenue
- JGH N/A
- ADCT $75,817,000.00
- Revenue This Year
- JGH N/A
- ADCT $9.19
- Revenue Next Year
- JGH N/A
- ADCT $16.27
- P/E Ratio
- JGH N/A
- ADCT N/A
- Revenue Growth
- JGH N/A
- ADCT 10.49
- 52 Week Low
- JGH $10.36
- ADCT $1.05
- 52 Week High
- JGH $12.85
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- JGH 58.82
- ADCT 84.08
- Support Level
- JGH $12.50
- ADCT $1.83
- Resistance Level
- JGH $12.67
- ADCT $2.35
- Average True Range (ATR)
- JGH 0.13
- ADCT 0.36
- MACD
- JGH 0.01
- ADCT 0.17
- Stochastic Oscillator
- JGH 79.75
- ADCT 98.91
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).